Loading...
Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor Positive, HER2 Negative Patients Likely to Benefit From Neoadjuvant Chemotherapy
BACKGROUND: The benefit of neoadjuvant therapy (NAC) in patients with estrogen receptor positive (ER+) HER2− breast cancers and in invasive lobular cancer (ILC) is uncertain due to low rates of pathologic complete response (pCR). Our aim was to determine if pathologic features can identify subsets l...
Na minha lista:
| Udgivet i: | Ann Surg Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5649343/ https://ncbi.nlm.nih.gov/pubmed/28560596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-017-5898-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|